Innoviva Specialty Therapeutics, a wholly-owned subsidiary of Innoviva, Inc. announced that David Altarac, MD, has been appointed as Chief Medical Officer leading the company's Clinical, Regulatory, Safety, and Medical Affairs teams. Dr. Altarac is an infectious disease physician and accomplished pharmaceutical executive with more than 20-years' experience leading clinical and regulatory functions at several leading biotechnology and pharmaceutical companies. Dr. Altarac previously served as the Chief Medical Officer of Innoviva Specialty Therapeutics following the 2023 acquisition of Entasis Therapeutics where he was Chief Medical Officer. Among his many accomplishments and contributions, Dr. Altarac was pivotal in guiding regulatory needs for Innoviva Specialty Therapeutics through the Entasis acquisition and portfolio transition.

His therapeutic-area expertise and knowledge of the U.S. regulatory environment was fundamental to the company's success in achieving U.S. Food and Drug Administration (FDA) approval of XACDURO (sulbactum-durlobactum for injection), and completion of the Phase III registration trial for zoliflodacin. Prior to serving as CMO of Entasis, Dr. Altarac was most notably Senior Vice President, Head, Global Regulatory Affairs, Safety, RD Quality and Compliance organizations, at Shire Pharmaceuticals and Vice President of Regulatory Affairs Emerging Markets RD, Worldwide Regulatory Teams and Worldwide Product Labeling at Merck Co.